Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-10-03
2010-02-23
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07666597
ABSTRACT:
The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG or GC genotype is at increased risk for tardive dyskinesia as compared to a subject comprising the GG genotype. Kits for practicing the method are also disclosed.
REFERENCES:
Segman et al. (Molecular Psychiatry 1999 vol. 4 p. 247).
Srivastava et al. (Pharmacogenetics and Genomics 2006 vol. 16 p. 111).
Nikoloff et al. (The pharmacogenomics Journal 2002 vol. 2 p. 400).
Sachdev et al. (Australian and New Zealand Journal of Psychiatry 2000 vol. 34 p. 355).
Jonsson et al. (Psychiatric Geneicts 2003 vol. 13 p. 1).
Accili D, et al. (1996). A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 93(5),1945-9.
Apa (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
Basile VS, et al. (1999). Association of the Msel polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21,17-27.
Buckland PR, et al. (1992). Changes in dopamine DI, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 106(4), 479-83.
Tardive dyskinesia and neuroleptics: from dogma to reason. Casey DE, Gardos G (ed). American Psychiatric Press, Inc., Washington DC, USA, 1986. p. 40.
D'Souza U, et al. (1997). Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology 36(11-12), 1689-96.
Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (Revised edn). Washington, DC: Department of Health, Education and Welfare.
Gyertyan & Saghy (2004). Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U99194A and SB27701. Behav Pharmacol 15(4),253-262.
Kaiser R, et al. (2002). Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia. Molecular Psychiatry 7, 695-705.
Kling-Petersen T, et al. (1995). Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect 102(3), 209-20.
Lahiri & Nurnburger Jr (1991). A rapid non-enzymatic method for the preparation of HMV DNA from blood for RFLP analysis. Nucleic Acids Research 19, 5444.
Lerer B, et al. (2002). Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9G1y polymorphism. Neuropsychopharmacology 27(1), 105-119.
Lundstrom & Turpin (1996). Proposed schizophrenia-related gene polymorphism: expression of the Ser9G1y mutant human dopamine D3 receptor with the,Semliki Forest virus system. Biochem Biophys Res Commun 225(3), 1068-72.
Muller DJ, et al. (2001). Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 104(5), 375-9.
Muller DJ, et al. (2004). Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics Journal 4, 77-87.
Schooler& Kane (1982), Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39, 486-487.
Suzuki M, et al. (1998). D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779(1-2),58-74.
Tarsy & Baldessarini (2006). Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Movement Disorders. Published online: Mar. 10, 2006. DOI: 10.1002/mds.20823.
Uitenbroek DG (1997). “SISA-Binomial”, available: http://home.clara.net/sisa/binomial.htm.
Kennedy James Lowery
Zai Clement C.
Bausch Sarae
Centre for Addiction and Mental Health
Salmon Katherine
Smith , Gambrell & Russell, LLP
Sundby, Esq. Suzannah K.
LandOfFree
Marker for tardive dyskinesia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Marker for tardive dyskinesia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Marker for tardive dyskinesia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209921